Clinical Trials Logo
  1. Home
  2. Advanced Gastric Adenocarcinoma
  3. NCT06238752

First-line Apatinib Combined With Tislelizumab and Chemotherapy for Advanced GC — RENMIN-213  

Advanced Gastric Adenocarcinoma Clinical Trial

Official title:
First-line Apatinib Combined With Tislelizumab and Chemotherapy for Advanced Gastric and Gastroesophageal Junction(G/GEJ) Adenocarcinoma Patients With Poor Prognosis: A Prospective Exploratory Study

Clinical Trial Summary

In this clinical study, investigators explore the efficacy and safety of a combination therapy regimen with antiangiogenic agent (apatinib), ICI (tislelizumab), and chemotherapy (capecitabine+ Oxaliplatin, XELOX) as first-line treatment for HER2-negative, advanced G/GEJ cancer patients with signet ring cell carcinoma or peritoneal metastasis.

Clinical Trial Description

Patients received 8 cycles of apatinib (250 mg, qd, d1-14), tislelizumab (200 mg d1), and oxaliplatin (130 mg/m2, d1) plus oral capecitabine (1000 mg/m2, bid, d1-14) every 3 weeks, with a maintenance therapy with apatinib plus tislelizumab for a maximum of 1 year. Homogeneous patients receiving ICIs combined with chemotherapy at the same time were deemed as the control group for efficacy. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06238752
Study type Interventional
Source Renmin Hospital of Wuhan University
Contact
Status Completed
Phase Phase 2
Start date March 1, 2021
Completion date January 1, 2024
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04977193 - A Study to Evaluate the Safety and Efficacy of ly011 Cell Injection in the Treatment of Advanced Gastric Adenocarcinoma Early Phase 1
Recruiting NCT04993378 - Prospectively Predict the Efficacy of Treatment of Gastrointestinal Tumors Based on Peripheral Multi-omics Liquid Biopsy
Recruiting NCT05583383 - A Study of the Advanced Adenocarcinoma of Stomach and Gastroesophageal Junction With Camrelizumab+SOX Control Camrelizumab+SOX+ Trastuzumab N/A
Not yet recruiting NCT06203600 - Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, The PARAMMUNE Trial Phase 2/Phase 3
Recruiting NCT04209686 - Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma Phase 2
Recruiting NCT02240524 - Efficacy of HIPEC in the Treatment of Patients With Locally Advanced Gastric Cancer Phase 3
Completed NCT02447380 - Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Advanced Gastric Adenocarcinoma Patients With MET Overexpression as a Second-line Treatment Phase 2
Recruiting NCT05677490 - mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma Phase 3
Completed NCT02448329 - Study of AZD1775 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring TP53 Mutation as a Second-line Chemotherapy Phase 2
Completed NCT02615730 - PI3Kβ Selective Inhibitor With Paclitaxel, Advanced Gastric Adenocarcinoma Phase 1/Phase 2
Recruiting NCT05041153 - Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma Early Phase 1
Terminated NCT02449655 - Trial of AZD5363 Plus Paclitaxel /AZD2014 Plus Paclitaxel in Biomarker Negative (PIK3CA/MEK/RAS/TP53/MET) Gastric Adenocarcinoma Patients as Second-line Chemotherapy Phase 2
Completed NCT02449551 - Study of AZD6094 (Volitinib) in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Third-line Treatment Phase 2
Not yet recruiting NCT04174339 - PD-1 Antibody(SHR-1210) Plus Apatinib Combined With POF in Advanced Gastric Cancer N/A
Completed NCT02599324 - Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors Phase 1/Phase 2
Recruiting NCT06028737 - Total Neoadjuvant Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer Phase 2/Phase 3
Recruiting NCT04675866 - Camrelizumab Combined With Albumin-bound Paclitaxel and S-1 in the Treatment of Advanced Gastric Cancer N/A
Completed NCT02447406 - Phase Ib, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Any Solid Cancer and Sequential Phase II, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Second Line Treatment Phase 1/Phase 2
Recruiting NCT03159819 - Clinical Study of CAR-CLD18 T Cells in Patients With Advanced Gastric Adenocarcinoma and Pancreatic Adenocarcinoma N/A